ACE and chronic kidney disease: The first target to consider is the reduction of albuminuria with angiotensin-convertingenzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) based on evidence from a post hoc analysis of the ONTARGET/TRANSCEND trials, 25% of the participants in which had CKD [81].